nach oben

Die MKG-Chirurgie

Erschienen in:

01.09.2015 | Leitthema

Maligne Speicheldrüsentumoren

verfasst von: PD Dr. Dr. T. Ettl

Erschienen in: Die MKG-Chirurgie | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die malignen Speicheldrüsentumoren sind eine extrem heterogene Gruppe seltener Tumoren mit großer klinischer, pathologischer und molekularbiologischer Variabilität. Die chirurgische Resektion, oftmals mit adjuvanter Radio(Chemo)-Therapie, stellt die Behandlung der Wahl dar, während herkömmliche Chemotherapeutika kaum eine Wirksamkeit besitzen. Im Fokus der aktuellen Forschung steht die histologische und die molekularbiologische Charakterisierung der Tumoren. Neue Entitäten wie das „mammary analogue secretory carcinoma“ wurden beschrieben; darüber hinaus wurde der Begriff der High-Grade-Transformation mit Verlust der tumorspezifischen histologischen Merkmale geprägt. Ätiopathogenetisch zeigen verschiedene Subtypen wie z. B. das adenoidzystische Karzinom oder das Mukoepidermoidkarzinom spezifische chromosomale Aberrationen, die mit der Bildung von sog. Fusionsgenen einhergehen und für die Ausbildung sowie das Wachstum der entsprechenden Tumoren verantwortlich gemacht werden. Die zunehmende Erkenntnis dieser genomischen Alterationen und tumorspezifischen Signalwege eröffnet neue vielversprechende Möglichkeiten zielgerichteter molekularer Therapien im fortgeschrittenen Tumorstadium.

Barnes L, Eveson JW, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC Press, Lyon

Bjorndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homoe P, Sorensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C (2011) Salivary gland carcinoma in Denmark 1990–2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 47:677–682. doi:10.1016/j.oraloncology.2011.04.020PubMedCrossRef

Tian Z, Li L, Wang L, Hu Y, Li J (2010) Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39:235–242. doi:10.1016/j.ijom.2009.10.016PubMedCrossRef

Lloyd S, Yu JB, Ross DA, Wilson LD, Decker RH (2010) A prognostic index for predicting lymph node metastasis in minor salivary gland cancer. Int J Radiat Oncol Biol Phys 76:169–175PubMedCrossRef

Vander Poorten V, Hunt J, Bradley PJ, Haigentz M Jr, Rinaldo A, Mendenhall WM, Suarez C, Silver C, Takes RP, Ferlito A (2014) Recent trends in the management of minor salivary gland carcinoma. Head Neck 36:444–455. doi:10.1002/hed.23249PubMedCrossRef

Sultan I, Rodriguez-Galindo C, Al-Sharabati S, Guzzo M, Casanova M, Ferrari A (2011) Salivary gland carcinomas in children and adolescents: a population-based study, with comparison to adult cases. Head Neck 33(10):1476-1781CrossRef

Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum Pathol 32:596–604PubMedCrossRef

Weiler C, Zengel P, van der Wal JE, Guntinas-Lichius O, Schwarz S, Harrison JD, Kirchner T, Ihrler S (2010) Carcinoma ex pleomorphic adenoma with special reference to the prognostic significance of histological progression: a clinicopathological investigation of 41 cases. Histopathology 59:741–750CrossRef

Schwarz S, Stiegler C, Muller M, Ettl T, Brockhoff G, Zenk J, Agaimy A (2011) Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 58:557–570PubMedCrossRef

10.

Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, Ryska A, Leivo I, Kinkor Z, Michal M (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34:599–608. doi:10.1097/PAS.0b013e3181d9efccPubMed

11.

Cheuk W, Chan JK (2007) Advances in salivary gland pathology. Histopathology 51:1–20PubMedCrossRef

12.

Seethala RR (2011) Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 18:29–45. doi:10.1097/PAP.0b013e318202645aPubMedCrossRef

13.

Amit M, Binenbaum Y, Trejo-Leider L, Sharma K, Ramer N, Ramer I, Agbetoba A, Miles B, Yang X, Lei D, Bjorndal K, Godballe C, Mucke T, Wolff KD, Eckardt AM, Copelli C, Sesenna E, Palmer F, Ganly I, Patel S, Gil Z (2014) International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck. doi:10.1002/hed.23710

14.

Pitman KT, Prokopakis EP, Aydogan B, Segas J, Carrau RL, Snyderman CH, Janecka IP, Hanna E, D’Amico F, Johnson JT (1999) The role of skull base surgery for the treatment of adenoid cystic carcinoma of the sinonasal tract. Head Neck 21:402–407PubMedCrossRef

15.

Bhayani MK, Yener M, El-Naggar A, Garden A, Hanna EY, Weber RS, Kupferman ME (2012) Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands. Cancer 118:2872–2878. doi:10.1002/cncr.26549PubMedCrossRef

16.

Zhang CY, Xia RH, Han J, Wang BS, Tian WD, Zhong LP, Tian Z, Wang LZ, Hu YH, Li J (2013) Adenoid cystic carcinoma of the head and neck: clinicopathologic analysis of 218 cases in a Chinese population. Oral Surg Oral Med Oral Pathol Oral Radiol 115:368–375. doi:10.1016/j.oooo.2012.11.018PubMedCrossRef

17.

Amit M, Na’ara S, Sharma K, Ramer N, Ramer I, Agbetoba A, Glick J, Yang X, Lei D, Bjoerndal K, Godballe C, Mucke T, Klaus-Dietrich W, Eckardt AM, Copelli C, Sesenna E, Palmer F, Ganly I, Gil Z (2015) Elective neck dissection in patients with head and neck adenoid cystic carcinoma: an international collaborative study. Ann Surg Oncol 22:1353–1359. doi:10.1245/s10434-014-4106-7PubMedCrossRef

18.

Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, Owonikoko T, Ramalingam S, Shin DM, Khuri FR, Beitler JJ, Saba NF (2012) Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973–2007 surveillance, epidemiology, and end results data. Cancer 118:4444–4451. doi:10.1002/cncr.27408PubMedCrossRef

19.

Ciccolallo L, Licitra L, Cantu G, Gatta G (2009) Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol 45:669–674. doi:10.1016/j.oraloncology.2008.10.010PubMedCrossRef

20.

Ettl T, Schwarz-Furlan S, Gosau M, Reichert TE (2012) Salivary gland carcinomas. Oral Maxillofac Surg 16:267–283. doi:10.1007/s10006-012-0350-9PubMedCrossRef

21.

Goode RK, Auclair PL, Ellis GL (1998) Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82:1217–1224PubMedCrossRef

22.

Brandwein MS, Ivanov K, Wallace DI, Hille JJ, Wang B, Fahmy A, Bodian C, Urken ML, Gnepp DR, Huvos A, Lumerman H, Mills SE (2001) Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 25:835–845PubMedCrossRef

23.

Chen MM, Roman SA, Sosa JA, Judson BL (2014) Histologic grade as prognostic indicator for mucoepidermoid carcinoma: a population-level analysis of 2400 patients. Head Neck 36:158–163. doi:10.1002/hed.23256PubMedCrossRef

24.

Liu S, Ow A, Ruan M, Yang W, Zhang C, Wang L, Zhang C (2014) Prognostic factors in primary salivary gland mucoepidermoid carcinoma: an analysis of 376 cases in an Eastern Chinese population. Int J Oral Maxillofac Surg 43:667–673. doi:10.1016/j.ijom.2014.01.008PubMedCrossRef

25.

McHugh CH, Roberts DB, El-Naggar AK, Hanna EY, Garden AS, Kies MS, Weber RS, Kupferman ME (2012) Prognostic factors in mucoepidermoid carcinoma of the salivary glands. Cancer 118:3928–3936. doi:10.1002/cncr.26697PubMedCrossRef

26.

Biron VL, Lentsch EJ, Gerry DR, Bewley AF (2014) Factors influencing survival in acinic cell carcinoma: a retrospective survival analysis of 2061 patients. Head Neck. doi:10.1002/hed.23686

27.

Patel NR, Sanghvi S, Khan MN, Husain Q, Baredes S, Eloy JA (2014) Demographic trends and disease-specific survival in salivary acinic cell carcinoma: an analysis of 1129 cases. Laryngoscope 124:172–178. doi:10.1002/lary.24231PubMedCrossRef

28.

Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR (1999) National Cancer Data Base report on cancer of the head and neck: acinic cell carcinoma. Head Neck 21:297–309PubMedCrossRef

29.

Lewis JE, Olsen KD, Weiland LH (1991) Acinic cell carcinoma. Clinicopathologic review. Cancer 67:172–179PubMedCrossRef

30.

Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, Shah JP, Wong RJ, Ghossein RA, Lee NY (2009) Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer 115:2128–2137. doi:10.1002/cncr.24259PubMedCrossRef

31.

Skalova A, Sima R, Vanecek T, Muller S, Korabecna M, Nemcova J, Elmberger G, Leivo I, Passador-Santos F, Walter J, Rousarova M, Jedlickova K, Curik R, Geierova M, Michal M (2009) Acinic cell carcinoma with high-grade transformation: a report of 9 cases with immunohistochemical study and analysis of TP53 and HER-2/neu genes. Am J Surg Pathol 33:1137–1145. doi:10.1097/PAS.0b013e3181a38e1cPubMedCrossRef

32.

Antony J, Gopalan V, Smith RA, Lam AK (2012) Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol 6:1–9. doi:10.1007/s12105-011-0281-zPubMedCentralPubMedCrossRef

33.

Di Palma S (2013) Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol 7(Suppl 1):S68–S76. doi:10.1007/s12105-013-0454-zPubMedCrossRef

34.

Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134–148PubMedCrossRef

35.

Patel TD, Vazquez A, Marchiano E, Park RC, Baredes S, Eloy JA (2015) Polymorphous low-grade adenocarcinoma of the head and neck: a population-based study of 460 cases. Laryngoscope. doi:10.1002/lary.25266

36.

Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D (2013) Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res 19:480–490. doi:10.1158/1078-0432.ccr-12-1842PubMedCrossRef

37.

Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, Luvison A, Roy S, Seethala RR, Nikiforova MN (2015) Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol. doi:10.1097/pas.0000000000000410

38.

Williams L, Thompson LD, Seethala RR, Weinreb I, Assaad AM, Tuluc M, Ud Din N, Purgina B, Lai C, Griffith CC, Chiosea SI (2015) Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression. Am J Surg Pathol 39:705–713. doi:10.1097/pas.0000000000000413PubMedCrossRef

39.

Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T (2005) Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 103:2526–2533PubMedCrossRef

40.

Jayaprakash V, Merzianu M, Warren GW, Arshad H, Hicks WL Jr, Rigual NR, Sullivan MA, Seshadri M, Marshall JR, Cohan DM, Zhao Y, Singh AK (2014) Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the surveillance, epidemiology, and end results database. Head Neck 36:694–701. doi:10.1002/hed.23350PubMedCentralPubMedCrossRef

41.

Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, Reichert TE, Gosau M, Kuhnel T, Brockhoff G, Schwarz S (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921–931PubMedCrossRef

42.

Johnston ML, Huang SH, Waldron JN, Atenafu EG, Chan K, Cummings BJ, Gilbert RW, Goldstein D, Gullane PJ, Irish JC, Perez-Ordonez B, Weinreb I, Bayley A, Cho J, Dawson LA, Hope A, Ringash J, Witterick IJ, O’Sullivan B, Kim J (2015) Salivary duct carcinoma: treatment, outcomes and patterns of failure. Head Neck. doi:10.1002/hed.24107

43.

Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29:e727–e730PubMedCrossRef

44.

Soper MS, Iganej S, Thompson LD (2014) Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Head Neck 36:E4–E7. doi:10.1002/hed.23383PubMedCrossRef

45.

Huang AT, Tang C, Bell D, Yener M, Izquierdo L, Frank SJ, El-Naggar AK, Hanna EY, Weber RS, Kupferman ME (2015) Prognostic factors in adenocarcinoma of the salivary glands. Oral Oncol. doi:10.1016/j.oraloncology.2015.03.005

46.

Jouzdani E, Yachouh J, Costes V, Faillie JL, Cartier C, Poizat F, Pierre G, Burcia V, Makeieff M, Crampette L, Guerrier B, Garrel R (2010) Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 46:323–331PubMedCrossRef

47.

Nagao T (2014) Head and Neck Pathology: SY13-3 HIGH-GRADE TRANSFORMATION IN SALIVARY GLAND CARCINOMAS. Pathology 46(Suppl 2):S20. doi:10.1097/01.PAT.0000454116.19061.fdCrossRef

48.

Brandwein-Gensler M, Wei S (2014) Envisioning the next WHO head and neck classification. Head Neck Pathol 8:1–15. doi:10.1007/s12105-014-0529-5PubMedCentralPubMedCrossRef

49.

Stenman G, Persson F, Andersson MK (2014) Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers. Oral Oncol 50:683–690. doi:10.1016/j.oraloncology.2014.04.008PubMedCrossRef

50.

Simpson RH, Skalova A, Di Palma S, Leivo I (2014) Recent advances in the diagnostic pathology of salivary carcinomas. Virchows Arch 465:371–384. doi:10.1007/s00428-014-1639-xPubMedCrossRef

51.

Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY (2014) Adenoid cystic carcinoma: a review of recent advances, molecular targets and clinical trials. Head Neck. doi:10.1002/hed.23925

52.

Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, Chan TA (2013) The mutational landscape of adenoid cystic carcinoma. Nat Genet 45:791–798. doi:10.1038/ng.2643PubMedCrossRef

53.

Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK, Natrajan R, Gauthier A, Di Palma S, Shousha S, Gatalica Z, Topfer C, Vukovic V, A’Hern R, Weigelt B, Vincent-Salomon A, Stenman G, Rubin BP, Reis-Filho JS (2013) Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology 62:543–550. doi:10.1111/his.12050PubMedCrossRef

54.

Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C (2010) Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer research 70:9143–9152. doi:10.1158/0008-5472.can-10-1758PubMedCrossRef

55.

Ettl T, Schwarz-Furlan S, Haubner F, Muller S, Zenk J, Gosau M, Reichert TE, Zeitler K (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol 48(9):822–830PubMedCrossRef

56.

Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266–2274PubMedCentralPubMedCrossRef

57.

Prat A, Parera M, Reyes V, Peralta S, Cedres S, Andreu J, Huguet P, del Campo JM (2008) Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck 30:680–683. doi:10.1002/hed.20714PubMedCrossRef

58.

Griffith CC, Seethala RR, Luvison A, Miller M, Chiosea SI (2013) PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol 37:1201–1207. doi:10.1097/PAS.0b013e3182880d5aPubMedCrossRef

59.

Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, Kuhnel T, Gosau M, Zeitler K, Schwarz S, Brockhoff G (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726PubMedCentralPubMedCrossRef

60.

Lee YY, Wong KT, King AD, Ahuja AT (2008) Imaging of salivary gland tumours. Eur J Radiol 66:419–436PubMedCrossRef

61.

Burke CJ, Thomas RH, Howlett D (2011) Imaging the major salivary glands. Br J Oral Maxillofac Surg 49:261–269. doi:10.1016/j.bjoms.2010.03.002PubMedCrossRef

62.

Lam PD, Kuribayashi A, Imaizumi A, Sakamoto J, Sumi Y, Yoshino N, Kurabayashi T (2015) Differentiating benign and malignant salivary gland tumours: diagnostic criteria and the accuracy of dynamic contrast-enhanced MRI with high temporal resolution. Br J Radiol 88:20140685. doi:10.1259/bjr.20140685PubMedCrossRef

63.

Habermann CR, Arndt C, Graessner J, Diestel L, Petersen KU, Reitmeier F, Ussmueller JO, Adam G, Jaehne M (2009) Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? AJNR Am J Neuroradiol 30:591–596. doi:10.3174/ajnr.A1412PubMedCrossRef

64.

Schmidt RL, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of fine-needle aspiration cytology for parotid gland lesions. Am J Clin Pathol 136:45–59PubMedCrossRef

65.

Christensen RK, Bjorndal K, Godballe C, Krogdahl A (2010) Value of fine-needle aspiration biopsy of salivary gland lesions. Head Neck 32:104–108PubMed

66.

Kim BY, Hyeon J, Ryu G, Choi N, Baek CH, Ko YH, Jeong HS (2013) Diagnostic accuracy of fine needle aspiration cytology for high-grade salivary gland tumors. Ann Surg Oncol 20:2380–2387. doi:10.1245/s10434-013-2903-zPubMedCrossRef

67.

Schmidt RL, Hall BJ, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of ultrasound-guided core needle biopsy for salivary gland lesions. Am J Clin Pathol 136:516–526PubMedCrossRef

68.

Haldar S, Mandalia U, Skelton E, Chow V, Turner SS, Ramesar K, Tighe D, Williams M, Howlett D (2015) Diagnostic investigation of parotid neoplasms: a 16-year experience of freehand fine needle aspiration cytology and ultrasound-guided core needle biopsy. Int J Oral Maxillofac Surg 44:151–157. doi:10.1016/j.ijom.2014.09.025PubMedCrossRef

69.

Olsen KD, Moore EJ, Lewis JE (2013) Frozen section pathology for decision making in parotid surgery. JAMA Otolaryngol Head Neck Surg 139:1275–1278. doi:10.1001/jamaoto.2013.5217PubMedCrossRef

70.

Schmidt RL, Hunt JP, Hall BJ, Wilson AR, Layfield LJ (2011) A systematic review and meta-analysis of the diagnostic accuracy of frozen section for parotid gland lesions. Am J Clin Pathol 136:729–738PubMedCrossRef

71.

Zbaren P, Guelat D, Loosli H, Stauffer E (2008) Parotid tumors: fine-needle aspiration and/or frozen section. Otolaryngol Head Neck Surg 139:811–815. doi:10.1016/j.otohns.2008.09.013PubMedCrossRef

72.

Razfar A, Heron DE, Branstetter BF, Seethala RR, Ferris RL (2010) Positron emission tomography-computed tomography adds to the management of salivary gland malignancies. Laryngoscope 120:734–738. doi:10.1002/lary.20829PubMedCrossRef

73.

Park HL, Yoo Ie R, Lee N, Yoon H, Choi EK, Choi HS, Kim SH (2013) The value of F-18 FDG PET for planning treatment and detecting recurrence in malignant salivary gland tumors: comparison with conventional imaging studies. Nucl Med Mol Imaging 47:242–248. doi:10.1007/s13139-013-0222-8PubMedCentralPubMedCrossRef

74.

Keyes JW Jr, Watson NE Jr, Williams DW 3rd, Greven KM, McGuirt WF (1997) FDG PET in head and neck cancer. AJR Am J Roentgenol 169:1663–1669. doi:10.2214/ajr.169.6.9393187PubMedCrossRef

75.

Hadiprodjo D, Ryan T, Truong MT, Mercier G, Subramaniam RM (2012) Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR Am J Roentgenol 198:W185–W190. doi:10.2214/ajr.11.7172PubMedCrossRef

76.

Kim MJ, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY (2013) Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection. Ann Surg Oncol 20:899–905. doi:10.1245/s10434-012-2716-5PubMedCrossRef

77.

Sobin LH, Compton CC (2010) TNM seventh edition: what’s new, what’s changed: communication from the International union against cancer and the American Joint Committee on Cancer. Cancer 116:5336–5339. doi:10.1002/cncr.25537PubMedCrossRef

78.

Kaszuba SM, Zafereo ME, Rosenthal DI, El-Naggar AK, Weber RS (2007) Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg 133:546–550. doi:10.1001/archotol.133.6.546PubMedCrossRef

79.

Ryu IS, Roh JL, Cho KJ, Lee SW, Choi SH, Nam SY, Kim SY (2013) Clinical outcomes of patients with salivary gland carcinomas preoperatively misdiagnosed as benign lesions. Head Neck 35:1764–1770. doi:10.1002/hed.23228PubMedCrossRef

80.

Guntinas-Lichius O, Klussmann JP, Schroeder U, Quante G, Jungehuelsing M, Stennert E (2004) Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope 114:949–956. doi:10.1097/00005537-200405000-00032PubMedCrossRef

81.

Lim YC, Lee SY, Kim K, Lee JS, Koo BS, Shin HA, Choi EC (2005) Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol 41:1021–1027. doi:10.1016/j.oraloncology.2005.06.004PubMedCrossRef

82.

Sood AJ, Houlton JJ, Nguyen SA, Gillespie MB (2015) Facial nerve monitoring during parotidectomy: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 152:631–637. doi:10.1177/0194599814568779PubMedCrossRef

83.

Eisele DW, Wang SJ, Orloff LA (2010) Electrophysiologic facial nerve monitoring during parotidectomy. Head Neck 32:399–405. doi:10.1002/hed.21190PubMed

84.

Terhaard C, Lubsen H, Tan B, Merkx T, van der Laan B, Baatenburg de Jong R, Manni H, Knegt P (2006) Facial nerve function in carcinoma of the parotid gland. Eur J Cancer 42:2744–2750PubMedCrossRef

85.

Leong SC, Lesser TH (2013) Long-term outcomes of facial nerve function in irradiated and nonirradiated nerve grafts. Ann Otol Rhinol Laryngol 122:695–700PubMedCrossRef

86.

Cannady SB, Seth R, Fritz MA, Alam DS, Wax MK (2010) Total parotidectomy defect reconstruction using the buried free flap. Otolaryngol Head Neck Surg 143:637–643. doi:10.1016/j.otohns.2010.08.014PubMedCrossRef

87.

Elliott RM, Weinstein GS, Low DW, Wu LC (2011) Reconstruction of complex total parotidectomy defects using the free anterolateral thigh flap: a classification system and algorithm. Ann Plast Surg 66:429–437. doi:10.1097/SAP.0b013e31820bcc2ePubMedCrossRef

88.

Sanabria A, Kowalski LP, Bradley PJ, Hartl DM, Bradford CR, de Bree R, Rinaldo A, Ferlito A (2012) Sternocleidomastoid muscle flap in preventing Frey’s syndrome after parotidectomy: a systematic review. Head Neck 34:589–598. doi:10.1002/hed.21722PubMedCrossRef

89.

Li C, Yang X, Pan J, Shi Z, Li L (2013) Graft for prevention of Frey syndrome after parotidectomy: a systematic review and meta-analysis of randomized controlled trials. J Oral Maxillofac Surg 71:419–427. doi:10.1016/j.joms.2012.06.007PubMedCrossRef

90.

Witt RL, Pribitkin EA (2013) How can Frey’s syndrome be prevented or treated following parotid surgery? Laryngoscope 123:1573–1574. doi:10.1002/lary.23779PubMedCrossRef

91.

Ettl T, Gosau M, Brockhoff G, Schwarz-Furlan S, Agaimy A, Reichert TE, Rohrmeier C, Zenk J, Iro H (2014) Predictors of cervical lymph node metastasis in salivary gland cancer. Head Neck 36:517–523. doi:10.1002/hed.23332PubMedCrossRef

92.

Lim CM, Gilbert M, Johnson JT, Kim S (2015) Is level V neck dissection necessary in primary parotid cancer? Laryngoscope 125:118–121. doi:10.1002/lary.24772PubMedCrossRef

93.

Lau VH, Aouad R, Farwell DG, Donald PJ, Chen AM (2014) Patterns of nodal involvement for clinically N0 salivary gland carcinoma: refining the role of elective neck irradiation. Head Neck 36:1435–1439. doi:10.1002/hed.23467PubMedCrossRef

94.

Zbaren P, Schupbach J, Nuyens M, Stauffer E (2005) Elective neck dissection versus observation in primary parotid carcinoma. Otolaryngol Head Neck Surg 132:387–391. doi:10.1016/j.otohns.2004.09.029PubMedCrossRef

95.

Armstrong JG, Harrison LB, Thaler HT, Friedlander-Klar H, Fass DE, Zelefsky MJ, Shah JP, Strong EW, Spiro RH (1992) The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 69:615–619PubMedCrossRef

96.

Ali S, Palmer FL, DiLorenzo M, Shah JP, Patel SG, Ganly I (2014) Treatment of the neck in carcinoma of the parotid gland. Ann Surg Oncol 21:3042–3048. doi:10.1245/s10434-014-3681-yPubMedCrossRef

97.

Bhattacharyya N, Fried MP (2005) Determinants of survival in parotid gland carcinoma: a population-based study. Am J Otolaryngol 26:39–44PubMedCrossRef

98.

Zbaren P, Schupbach J, Nuyens M, Stauffer E, Greiner R, Hausler R (2003) Carcinoma of the parotid gland. Am J Surg 186:57–62PubMedCrossRef

99.

Chisholm EJ, Elmiyeh B, Dwivedi RC, Fisher C, Thway K, Kerawala C, Clarke PM, Rhys-Evans PH (2011) Anatomic distribution of cervical lymph node spread in parotid carcinoma. Head Neck 33:513–515. doi:10.1002/hed.21479PubMedCrossRef

100.

Cerda T, Sun XS, Vignot S, Marcy PY, Baujat B, Baglin AC, Ali AM, Testelin S, Reyt E, Janot F, Thariat J (2014) A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). Crit Rev Oncol Hematol 91:142–158. doi:10.1016/j.critrevonc.2014.02.002PubMedCrossRef

101.

Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116:290–293PubMedCrossRef

102.

Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van Den Ende PL, Burlage F (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61:103–111PubMedCrossRef

103.

Shah K, Javed F, Alcock C, Shah KA, Pretorius P, Milford CA (2011) Parotid cancer treatment with surgery followed by radiotherapy in Oxford over 15 years. Ann R Coll Surg Engl 93:218–222. doi:10.1308/003588411x565969PubMedCentralPubMedCrossRef

104.

Garden AS, el-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37:79–85PubMedCrossRef

105.

Al-Mamgani A, van Rooij P, Verduijn GM, Meeuwis CA, Levendag PC (2012) Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den Hoed Cancer Center. Int J Radiat Oncol Biol Phys 84:189–195. doi:10.1016/j.ijrobp.2011.11.045PubMedCrossRef

106.

Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR, Balboni TA, Tishler RB (2012) Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys 82:308–314. doi:10.1016/j.ijrobp.2010.09.042PubMedCrossRef

107.

Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA (2011) Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol 3:31. doi:10.1186/1758-3284-3-31PubMedCentralPubMedCrossRef

108.

Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A (2009) Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 135:687–692. doi:10.1001/archoto.2009.70PubMedCrossRef

109.

Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK (2006) Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 66:1044–1050. doi:10.1016/j.ijrobp.2006.06.050PubMedCrossRef

110.

Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB (2005) Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103:2544–2550. doi:10.1002/cncr.21083PubMedCrossRef

111.

Laramore GE, Krall JM, Griffin TW, Duncan W, Richter MP, Saroja KR, Maor MH, Davis LW (1993) Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27:235–240PubMedCrossRef

112.

Douglas JG, Laramore GE, Austin-Seymour M, Koh W, Stelzer K, Griffin TW (2000) Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46:551–557PubMedCrossRef

113.

Laurie SA, Siu LL, Winquist E, Maksymiuk A, Harnett EL, Walsh W, Tu D, Parulekar WR (2010) A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group. Cancer 116:362–368. doi:10.1002/cncr.24745PubMedCrossRef

114.

Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28:197–204. doi:10.1002/hed.20327PubMedCrossRef

115.

Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY (2012) Biology and management of salivary gland cancers. Semin Radiat Oncol 22:245–253. doi:10.1016/j.semradonc.2012.03.009PubMedCrossRef

116.

Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, Siu LL (2012) A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 23:1562–1570. doi:10.1093/annonc/mdr522PubMedCrossRef

117.

Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978–3984PubMedCrossRef

118.

Locati LD, Perrone F, Cortelazzi B, Lo Vullo S, Bossi P, Dagrada G, Quattrone P, Bergamini C, Potepan P, Civelli E, Fallai C, Pilotti S, Licitra L (2014) Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed AR-positive salivary gland cancers. Head Neck. doi:10.1002/hed.23940

119.

Urban D, Rischin D, Angel C, D’Costa I, Solomon B (2015) Abiraterone in metastatic salivary duct carcinoma. J Natl Compr Canc Netw 13:288–290PubMed

120.

Jaspers HC, Verbist BM, Schoffelen R, Mattijssen V, Slootweg PJ, van der Graaf WT, van Herpen CM (2011) Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 29:e473–e476. doi:10.1200/jco.2010.32.8351PubMedCrossRef

121.

Tillmann B (2010) Atlas der Anatomie, 2. Aufl. Springer, Berlin

Titel: Maligne Speicheldrüsentumoren
verfasst von: PD Dr. Dr. T. Ettl
Publikationsdatum: 01.09.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Die MKG-Chirurgie / Ausgabe 3/2015
Print ISSN: 2731-748X
Elektronische ISSN: 2731-7498
DOI: https://doi.org/10.1007/s12285-015-0016-3

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | HNO-Chirurgie | Nachrichten

HNO-Op. auch mit über 90?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Maligne Speicheldrüsentumoren

Zusammenfassung

Neu im Fachgebiet Chirurgie

Hochrisiko-Eingriffe für postoperative Übelkeit

HNO-Op. auch mit über 90?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Wundheilungsstörung der Kopfhaut

Spielregeln bei der (zahn)ärztlichen Werbung

Mitteilungen der DGMKG

Resorption zweiter Molaren durch retinierte Weisheitszähne

Master-Studiengänge der Europäischen Fortbildungsakademie für Medizin und Zahnmedizin

PRESTO-Facelifttechnik

Neu im Fachgebiet Chirurgie

Hochrisiko-Eingriffe für postoperative Übelkeit

HNO-Op. auch mit über 90?

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“